Liedman (300289) in-depth report: the effect of channel integration gradually releases performance recovery
Liedman (300289): the increase of senior executives shows confidence that the company is at an inflection point
Liedman (300289) Annual report and Quarterly report comments: management updates the company's future business improvement potential is worth paying attention to
Liedman (300289): layout IVD full product line is expected to achieve multi-point flowering
Liedman (300289) report comments: industry competition intensifies revenue decline compared with the same period last year
Liedman (300289): waiting for chemiluminescence emission
Comments on Liedman (300289) Annual report: new products under short-term pressure of endogenous growth are expected to release gradually.
[Societe Generale Securities] Liedman: endogenous growth is under pressure for a short time, and new products are expected to release gradually.
Comments on Liedman's (300289) Annual report: Desai and table promote steady growth of performance
Liedman (300289): comments on performance KuaiBao
Leadman (300289): Desai joined forces to drive profit growth and is optimistic about subsequent sales of chemiluminescence reagents
Leadman (300289) Research Brief: Chemiluminescence emission is imminent, biochemical diagnosis synergizes to promote growth
[Southwest Securities] Leadman: Chemiluminescence emission is imminent, biochemical diagnosis synergizes to promote growth
Leadman (300289) Quarterly Review: Steady Growth in Performance and Increased Percentage
Leadman (300289) Briefing: The gradual enrichment of the product line drives the company's growth
[Guoyuan Securities] Leadman: The gradual enrichment of the product line drives the company's growth
Leadman (300289): Increasing R&D investment into the field of molecular diagnostics
Leadman (300289) Interim Report: Steady Growth in Performance and Increased Revenue Growth
[Dongwu Securities] Leadman: Increase investment in research and development to enter the field of molecular diagnostics
Leadman (300289) Interim Report: Performance Growth Is Steady, New Products Are Worth Looking forward to
No Data